Neoadjuvant antibody-drug conjugates for early-stage breast cancer: A systematic review and meta-analysis.
BACKGROUND Pathologic complete response (pCR) is a key endpoint of neoadjuvant therapy in early-stage breast cancer (EBC), associated with improved survival, particularly in triple-negative and human epidermal growth factor receptor 2 (HER2)-positive disease. More recently, antibody-drug conjugates (ADCs), established...